Rani Therapeutics Announces Topline Results from Phase 1 Study of RT-102 in Osteoporosis
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced positive